http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ce2f6aa978016cae3f8163f81482037
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Rojo |
| name | Federico Rojo |
| given-name | Federico |
| organization-name | Pathology Department, IIS-Fundación Jiménez Díaz, Avenida Reyes Católicos, Madrid 1Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, Madrid, Spain. Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain;; Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain; 6Pathology Department, IIS-Fundación Jimenez Diaz, Madrid, Spain. Pathology Department, IIS “Fundación Jiménez Diaz”, E-28040 Madrid, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain El Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz–Universidad Autónoma de MadridMadrid, Spainand Cancer Biomarkers Research Group, Fundacion Jimenez Diaz University Hospital Health Research Institute, UAM, 28040 Madrid, Spain Pathology Department, IIS‐Fundacion Jimenez Diaz‐UAM University Hospital “Fundacion Jimenez Diaz” 28040 Madrid Spain From the Montabone Unit for New Drug Development, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto dei Tumori di Milano; Southern Europe New Drugs Organization, Milano, Italy; Oncology Institute of Southern Switzerland, Bellinzona; Kantonsspital St. Gallen, St. Gallen, Switzerland; Cancer Research Program, Institut Municipal d'Investigació Mèdica-Hospital del Mar, Barcelona, Spain; and ARIAD Pharmaceuticals, Cambridge, MA. 2Pathology Service, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Pathology Fundación Jiménez Díaz University Hospital Madrid Spain; IIS‐Fundación Jimenez Diaz Center for Biomedical Network Research on Cancer (CIBERONC) Madrid Spain Pathology Department, University Hospital “Fundacion Jimenez Diaz,” Autonomous University of Madrid , Madrid , Spain 3Laboratory of Oncology Research, Medical Oncology Service, Vall d'Hebron Hospital, Barcelona, Spain; and Departments of 1Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain. Biomedical Research Networking Center in Oncology (CIBERONC) Madrid 28029 Spain; Department of Pathology Fundación Jiménez Díaz University Hospital Health Research Institute Madrid 28040 Spain 5Department of Pathology, IIS “Fundacion Jimenez Diaz University Hospital,” Madrid, Spain. 4GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; 13Fundación Jiménez Díaz, Madrid, Spain.; 20Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain. Authors' Affiliations: 1Cancer Research Program, 2Epithelial to Mesenchymal Transition Laboratory, Cancer Research Program, IMIM; 3Consulting Service on Methodology for Biomedical Research; Departments of 4Oncology and 5Pathology, Hospital del Mar; 6Universitat Pompeu Fabra, Barcelona; Departments of 7Pathology and 8Oncology, IIS-Fundación Jiménez Díaz, Madrid, Spain; Authors' Affiliations: 1Cancer Research Program, 2Epithelial to Mesenchymal Transition Laboratory, Cancer Research Program, IMIM; 3Consulting Service on Methodology for Biomedical Research; Departments of 4Oncology and 5Pathology, Hospital del Mar; 6Universitat Pompeu Fabra, Barcelona; Departments of 7Pathology and 8Oncology, IIS-Fundación Jiménez Díaz, Madrid, Spain 1Pathology, Departments of Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain Authors' Affiliations: 1Cancer Research Program, IMIM-Hospital del Mar; 2Pathology Service and 3Medical Oncology Service, Hospital del Mar-Parc de Salut MAR; 4Autonomous University of Barcelona; 5Medical Oncology Service, Hospital Clínic, Barcelona, Spain; 6Pathology Service, Fundacion Jimenez Diaz, Madrid, Spain; 7National Institute of Oncology and Radiobiology and 8Center of Molecular Immunology, Havana, Cuba; 9SENDO Foundation, Milan, Italy; and 10IOSI (Istituto Oncologico della Svizzera Italiana), Bellinzona, Switzerland; Authors' Affiliations: 1Cancer Research Program, IMIM-Hospital del Mar; 2Pathology Service and 3Medical Oncology Service, Hospital del Mar-Parc de Salut MAR; 4Autonomous University of Barcelona; 5Medical Oncology Service, Hospital Clínic, Barcelona, Spain; 6Pathology Service, Fundacion Jimenez Diaz, Madrid, Spain; 7National Institute of Oncology and Radiobiology and 8Center of Molecular Immunology, Havana, Cuba; 9SENDO Foundation, Milan, Italy; and 10IOSI (Istituto Oncologico della Svizzera Italiana), Bellinzona, Switzerland; Authors' Affiliations: 1Cancer Research Program, IMIM-Hospital del Mar; 2Pathology Service and 3Medical Oncology Service, Hospital del Mar-Parc de Salut MAR; 4Autonomous University of Barcelona; 5Medical Oncology Service, Hospital Clínic, Barcelona, Spain; 6Pathology Service, Fundacion Jimenez Diaz, Madrid, Spain; 7National Institute of Oncology and Radiobiology and 8Center of Molecular Immunology, Havana, Cuba; 9SENDO Foundation, Milan, Italy; and 10IOSI (Istituto Oncologico della Svizzera Italiana), Bellinzona, Switzerland 2Vall d' Hebron University Hospital, Barcelona, Spain, Pathology Department, IIS Fundacion Jimenez Diaz , Madrid, Spain 1Pathology and Departments of Pathology Department, University Hospital “Fundacion Jimenez Diaz”, Autonomous University of Madrid, E-28040 Madrid, Spain Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain. 5Department of Pathology, IIS-Fundación Jiménez Díaz-CIBERONC, Madrid, Spain. Pathology Department University Hospital “Fundacion Jimenez Diaz”, Autonomous University of Madrid Madrid Spain 2Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.; 3Department of Pathology, IIS ‘Fundación Jiménez Diaz’, Madrid, Spain. oDepartment of Pathology, Fundación Jiménez Díaz, Madrid, Spain Pathology Department IIS‐Fundacion Jimenez Diaz‐UAM University Hospital “Fundacion Jimenez Diaz” Madrid Spain Pathology Department, Fundación Jiménez Díaz Health Research Institute (IIS-FJD), Madrid, Spain 6Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain Authors' Affiliations: 1GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Armilla, Granada, Spain; 2Medical Oncology Research Program and 3Department of Pathology, Vall d'Hebron University Hospital Research Institute; and 4Oncology Service, Hospital del Mar-IMIM, Barcelona, Spain; and 5Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands From the Department of Internal Medicine (Cancer Research), West German Cancer Center, and the Department of Pathology, University of Essen Medical School, Essen; Merck KGaA, Darmstadt, Germany; and the Laboratory of Oncology Research, Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain. Hospital Fundación Jimenez Diaz, Madrid, Spain From the Medical Oncology and Pathology Departments, Vall d’Hebron University Hospital, Barcelona, Spain; Medical Oncology Department, Sarah Cannon Cancer Center, Nashville, TN; Medical Oncology Department, Royal Marsden Hospital, London, United Kingdom; Novartis Oncology, Basel, Switzerland; and Novartis Oncology, Florham Park, NJ Pathology Department, Fundación Jimenez Díaz, Madrid, Spain Pathology Service, Hospital Fundación Jiménez Díaz, Madrid, Spain Pathology Department University Hospital “Fundacion Jimenez Diaz”, Autonomous University of Madrid Madrid E‐28040 Spain Center for Biomedical Network Research on Cancer (CIBERONC), Madrid 28019, Spain.; Department of Pathology, IIS Fundación Jiménez Díaz, Madrid 28040, Spain. Pathology Department Fundación Jiménez Díaz UAM Madrid Spain Authors' Affiliations: Departments of 1Pathology and 2Immunology, IIS-Fundación Jiménez Díaz, Madrid; 3Cancer Research Program; 4Microarray Core Facility (SAM), IMIM (Hospital del Mar Medical Research Institute); 5Department of Epidemiology and Evaluation, Hospital del Mar; 6Research Network on Health Services in Chronic Diseases (REDISSEC); 7Departments of Pathology, 8Medical Oncology, and 9Radiology Department, Hospital del Mar; and 10Universitat Pompeu Fabra, Barcelona, Spain; Authors' Affiliations: Departments of 1Pathology and 2Immunology, IIS-Fundación Jiménez Díaz, Madrid; 3Cancer Research Program; 4Microarray Core Facility (SAM), IMIM (Hospital del Mar Medical Research Institute); 5Department of Epidemiology and Evaluation, Hospital del Mar; 6Research Network on Health Services in Chronic Diseases (REDISSEC); 7Departments of Pathology, 8Medical Oncology, and 9Radiology Department, Hospital del Mar; and 10Universitat Pompeu Fabra, Barcelona, Spain Fundación Jiménez Díaz, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain, on behalf of GEICAM (Spanish Breast Cancer Group), Spain 6Pathology Department, IIS-Fundación Jiménez Díaz- CIBERONC, Madrid, Spain. Pathology Department IIS‐Fundación Jiménez Díaz‐UAM Madrid Spain Department of Pathology, Jiménez Díaz Foundation, 28040 Madrid, Spain; Center for Biomedical Network Research on Cancer (CIBERONC), 28040 Madrid, Spain Department of Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain From the Medical Oncology Service, Pathology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona; Department of Hematology and Medical Oncology, Hospital Clinic Universitario, University of Valencia; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain; Division of Medical Oncology, Department of Experimental and Clinical Medicine “F. Magrassi and A. Lanzara,” Second University of Naples, Naples, Italy; and Merck KGaA,... Pathology Department, IIS‐Fundacion Jimenez Diaz‐UAM University Hospital “Fundacion Jimenez Diaz” Madrid Spain Carlos Gomez-Martin, Elena Garralda, and Manuel Hidalgo, Spanish National Cancer Research Centre; Carlos Gomez-Martin, Jose Carlos Plaza, Fernando Lopez-Rios, and Manuel Hidalgo, Laboratorio Dianas Terapeuticas, Cenro Integral Oncologico Clara Campal, Hospital Universitario Sanchinarro; Federico Rojo and Ana Leon, Fundacion Jimenez Diaz, Madrid; Pilar Sanz-Moncasi, Hospital Royo-Villanova; Roberto Pazo-Cid and Elena del Valle, Hospital Universitario Miguel Servet, Zaragoza; Antonieta Salud and Felipe... Laboratori de Recerca Oncològica, Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron Barcelona 08035, Spain Hospital de Mar Research Institute–IMIM Barcelona Spain; IIS–Fundacion Jimenez Diaz Madrid Spain From the Vall d'Hebron University Hospital; Hospital Clinic, Barcelona; Instituto Valenciano de Oncologia; Universitat de Valencia, Hospital Clínico Universitario de Valencia and CESAT Valencia, Spain; and AstraZeneca, Wilmington, DE Pathology Department IIS‐Fundacion Jimenez Diaz‐UAM Madrid Spain Pathology Department, IIS‐Fundacion Jimenez Diaz‐UAM University Hospital ‘Fundacion Jimenez Diaz’ Madrid Spain Pathology Department Autonomous University of Madrid, University Hospital “Fundación Jiménez Diaz” 28040 Madrid Spain Pathology Department IIS‐Fundación Jiménez Díaz UAM Madrid Spain Biomedical Research Networking Centres‐Oncology (CIBERONC) Madrid Spain; Departments of Pathology and Surgery Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz Madrid Spain Pathology Department, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, Spain Pathology Department, University Hospital Fundación Jiménez Díaz, IIS-FJD, Universidad Autónoma de Madrid, Madrid, Spain; Pathology Department, IIS ‘Fundacion Jimenez Diaz’, Madrid, Spain Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain Pathology Department, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain Authors' Affiliations: Departments of 1Biostatistics and Computational Biology, and 2Medical Oncology; 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; 4Department of Biostatistics, Harvard School of Public Health; 5Department of Pathology; 6Translational Medicine Division, Brigham and Women's Hospital, Boston; 7Broad Institute of Harvard and MIT, Cambridge, Massachusetts; 8Sidney Kimmel Cancer Center; 9Department of Pathology, Johns Hopkins University, Baltimore, Maryland; 10Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York; and 11Hospital del Mar Research Institute-IMIM, Barcelona; and 12Hospital Parc Tauli, Sabadell, Spain Pathology Department, University Hospital "Fundacion Jimenez Diaz," Madrid, Spain. Fundación Jiménez Díaz, Madrid, Spain Centro de Investigación Biomedica en Red de Oncologia, CIBERONC-ISCIII, Spain; Pathology, Hospital Fundación Jimenez Díaz de Madrid, Madrid, Spain From the Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX; Arkansas Cancer Research Center, Little Rock, AR; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Cancer Institute of New Jersey, New Brunswick, NJ; Vall d’Hebron General Hospital, Barcelona, Spain; AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom; AstraZeneca Pharmaceuticals,... Pathology Department; IIS-Fundacion Jimenez Diaz-UAM, University Hospital “Fundacion Jimenez Diaz”; Madrid Spain 2Pathology Service, Vall d’Hebron University Hospital, Barcelona, Spain; 7Molecular Therapeutics and Biomarkers in Cancer Laboratory, Institut Hospital del Mar d'Investigacions Mèdiques, Hospital del Mar, Barcelona, Spain.; 10Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain.; 11Department of Pathology, Hospital del Mar, Barcelona, Spain. Pathology Department, University Hospital “Fundacion Jimenez Diaz,” Autonomous University of Madrid, Madrid, Spain Authors' Affiliations: 1Medical Oncology Service, Hospital del Mar; 2Cancer Research Program, IMIM; 3Autonomous University of Barcelona, Barcelona; 4Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 5The Cancer Therapeutics Unit/The Drug Development Unit, The Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom; 6SITEP, Department of Medicine, Institut Gustave Roussy, Villejuif, and University Paris-Sud, Paris; 7Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, CRCNA Nantes, France; 8F. Hoffmann-La Roche Ltd., Basel, Switzerland; 9F. Hoffmann-La Roche Ltd., Nutley, New Jersey; and 10.Roche Diagnostics GmbH, Penzberg, Germany; Authors' Affiliations: 1Medical Oncology Service, Hospital del Mar; 2Cancer Research Program, IMIM; 3Autonomous University of Barcelona, Barcelona; 4Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid, Spain; 5The Cancer Therapeutics Unit/The Drug Development Unit, The Institute of Cancer Research/Royal Marsden Hospital, London, United Kingdom; 6SITEP, Department of Medicine, Institut Gustave Roussy, Villejuif, and University Paris-Sud, Paris; 7Department of Nuclear Medicine/Center for PET/CT, University Hospital and ICO, René Gauducheau Cancer Center, INSERM Unit 892, CRCNA Nantes, France; 8F. Hoffmann-La Roche Ltd., Basel, Switzerland; 9F. Hoffmann-La Roche Ltd., Nutley, New Jersey; and 10.Roche Diagnostics GmbH, Penzberg, Germany Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain Pathology, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain the Institute of Health Research-Jimenez Diaz Foundation, CIBERONC, Madrid, Spain (Rojo) Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain; Department of Pathology, Fundación Jiménez Díaz, 28040 Madrid, Spain 1Cancer Research Program, IMIM-Hospital del Mar;; 2Pathology Service, Hospital del Mar;; 3Breast Disease Pathology Unit, Hospital del Mar;; 5Pathology Service and Pathology Department, IIS Fundación Jiménez Diaz, UAM, Madrid, Spain From the Oncology Service, Vall d’Hebron University Hospital; Dermatology Service, Hospital Clinic; Transfusio i Banc de Teixits, Vall d’Hebron Vall d’Hebron University Hospital, Barcelona, Spain; AstraZeneca Pharmaceuticals, Wilmington, DE; Oncology Service, M.D. Anderson Cancer Center, Houston, TX; Oncology Service, Harper Hospital, Detroit, MI; AstraZeneca Pharmaceuticals, Alderley Park; Department of Pharmacology, Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University,... 5Pathology Department, IIS-Hospital Universitario Fundación Jiménez Díaz–CIBERONC, Madrid, Spain. 5Pathology Department, CIBERONC- IIS-Fundación Jiménez Díaz, Madrid, Spain. Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain 2Pathology Department, IIS “Fundación Jiménez Diaz,” UAM, Madrid, Spain. Pathology Department, IIS, Fundacion Jimenez Diaz, UAM, Madrid, Spain. Pathology Department University Hospital “Fundacion Jimenez Diaz”, Autonomous University of Madrid 28040 Madrid Spain Authors' Affiliations: 1Translational Oncology Division, Health Research Institute and Oncology Department, University Hospital “Fundación Jiménez Díaz,” Autonomous University of Madrid; 2Pathology Department, IIS “Fundación Jiménez Díaz,” Madrid, Spain; and 3Medical Oncology Department, University Hospital of Vigo, Vigo, Spain |
Incoming Links
Total number of triples: 316.